Company profile
SPRUCE BIOSCIENCES, INC.
NASDAQ:SPRBBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Tildacerfont | phase2 | — | 4 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04457336 | phase2 | terminated | 2020-08-26 | 2024-02-09 | Spruce Biosciences | A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH |
| NCT04544410 | phase2 | terminated | 2021-02-22 | 2024-10-31 | Spruce Biosciences | A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH |
| NCT05128942 | phase2 | terminated | 2021-12-10 | 2025-01-31 | Spruce Biosciences | A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children Aged 2-17 Years With CAH |
| NCT05370521 | phase2 | terminated | 2022-05-15 | 2023-08-03 | Spruce Biosciences | A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens |
| NCT07579910 | phase3 | not_yet_recruiting | 2026-12-01 | 2033-08-01 | Spruce Biosciences | Intracerebroventricular Tralesinidase Alfa in Participants With MPS IIIB (Sanfilippo Syndrome Type B) |
FDA applications (0)
No records yet.